Drug
Linaclotide clinical trials
Also written Linzess, ASP0456 and MD-1100 Acetate.
- studies test it
- 43
- open now
- 3
- in phase 3
- 14
- first study started
- 2006
Keep track of what changes. Save the linaclotide studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
43 studies that test it; most in 2014 (7)
| Year | Studies |
|---|---|
| 2006 | 3 |
| 2007 | 1 |
| 2008 | 4 |
| 2009 | 1 |
| 2010 | 1 |
| 2011 | 1 |
| 2012 | 2 |
| 2013 | 2 |
| 2014 | 7 |
| 2015 | 6 |
| 2016 | 2 |
| 2018 | 1 |
| 2019 | 3 |
| 2021 | 3 |
| 2022 | 2 |
| 2023 | 1 |
| 2024 | 1 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 1
- 5
- Phase 2
- 13
- Phase 3
- 14
- Phase 4
- 6
- No phase
- 4
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 31 · Other 12
Ironwood Pharmaceuticals, Inc. (10) · Forest Laboratories (9) · Astellas Pharma Inc (6) · AbbVie (3) · University of Nottingham (2) · Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University (1) · University of Wisconsin, Madison (1) · Universitaire Ziekenhuizen KU Leuven (1)
Often tested with
Tested in the same studies.
Plecanatide (1) · Lactulose (1) · Polyethylene Glycols (1) · Senna Extract (1) · Sennosides (1)
Studies
Open first, then newest update. How each study uses linaclotide is read from its arms, and is right about nine times in ten.
Testing it · 43
- MRI Parameters as Biomarkers in Cystic Fibrosis (FEMPTO)Not yet recruitingNot applicableUniversity of NottinghamNCT07780344Written as Linaclotide 290 micrograms
- Proof of Principle Study for an Efficacy Trial of Linaclotide for Cystic FibrosisRecruitingEarly Phase 1University of NottinghamNCT07569419Written as Linaclotide 290 micrograms
- Clinical Study on the Application of Lactulose Combined with Linaclotide in Bowel Preparation for ColonoscopyEnrolling by invitationPhase 4Haifeng LanNCT06748638Written as Lactulose+ linaclotide
- Linaclotide in Treating Patients With Stages 0-3 Colorectal CancerActive, not recruitingPhase 2Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityNCT03796884Written as Linaclotide
- A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus Placebo in Pediatric Subjects, Ages 2 to 5 Years, With Functional ConstipationCompletedPhase 3AbbVieNCT05652205Written as Linaclotide
- GCC Agonist Signal in the Small IntestineCompletedPhase 1University of Wisconsin, MadisonNCT05107219Written as Linaclotide
- A Study to Assess Adverse Events and Change in Disease Activity in Pediatric Participants (Age 6 Months to <2 Years) With Functional Constipation Who Are Treated With LinaclotideCompletedPhase 2AbbVieNCT05760313Written as Linaclotide
- Effect to Linaclotide on Colonic MotilityCompletedPhase 4Universitaire Ziekenhuizen KU LeuvenNCT06989268Written as Linaclotide 290 micrograms
- Linaclotide Acetate in Preventing Colorectal Cancer in Healthy VolunteersCompletedPhase 1Mayo ClinicNCT01950403Written as linaclotide acetate
- Linaclotide Safety and Efficacy in Pediatric Participants, 6 to 17 Years of Age, With Irritable Bowel Syndrome With Constipation (IBS-C) or Functional Constipation (FC)CompletedPhase 3AbbVieNCT04026113Written as Linaclotide
- A Study to Evaluate Dose Responses of Efficacy and Safety of ASP0456 in Patient With Chronic ConstipationCompletedPhase 2Astellas Pharma IncNCT02425722Written as ASP0456
- A Study to Evaluate the Effect of ASP0456 in Patients With Constipation Predominant Irritable Bowel SyndromeCompletedPhase 2Astellas Pharma IncNCT01714843Written as linaclotide
- Phase III Study to Evaluate the Efficacy and Safety of ASP0456 in Patients With Constipation Predominant Irritable Bowel SyndromeCompletedPhase 3Astellas Pharma IncNCT02316899Written as linaclotide
- A Study of Oral Dosing of ASP0456 in Patients With Chronic ConstipationCompletedPhase 3Astellas Pharma IncNCT02809105Written as linaclotide
- Linaclotide Safety and Efficacy in 2 to 5-Year-Old Participants With Functional ConstipationCompletedPhase 2AllerganNCT04110145Written as Linaclotide
- Efficacy of Linaclotide in Patients With Overlapping Functional Gastrointestinal DisordersStatus unknownPhase 4RenJi HospitalNCT05134584Written as Linaclotide
- A Study of the Effect of Linaclotide on Abdominal Girth in Participants With Irritable Bowel Syndrome With Constipation (IBS-C)TerminatedPhase 4Ironwood Pharmaceuticals, Inc.NCT02837783Written as Linaclotide
- Effect and Safety of Polyethylene Glycol Combined With Linaclotide on Colon Cleansing for Patients With Chronic ConstipationStatus unknownNot applicableSecond Affiliated Hospital of Xi'an Jiaotong UniversityNCT05137145Written as Linaclotide
- Evaluation of Clinical Equivalence Between Two Linaclotide Products in the Treatment of Chronic Idiopathic ConstipationStatus unknownPhase 3Jiangsu Hansoh Pharmaceutical Co., Ltd.NCT04804267Written as Linaclotide
- A Safety and Efficacy Study of a Range of Linaclotide Doses Administered Orally to Children Ages 7-17 Years, With Irritable Bowel Syndrome With ConstipationTerminatedPhase 2Forest LaboratoriesNCT02559817Written as Linaclotide Dose A
Codes
What other systems call linaclotide · ClinicalTrials.gg INT005166
- MeSH (NLM) C523483linaclotideConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) N0TXR0XR5XLINACLOTIDEConfirmed FDA, NLM
- RxNorm 1307404One source FDA
- NCI Thesaurus C81001LinaclotideOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C523483 | linaclotide | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | N0TXR0XR5X | LINACLOTIDE | Confirmed FDA, NLM |
| RxNorm | 1307404 | — | One source FDA |
| NCI Thesaurus | C81001 | Linaclotide | One source FDA |
Also registered as linaclotide acetate (UNII NSF067KU1M).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.